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Angiotensin converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase with an
essential role in blood pressure homeostasis in mammals. ACE has long been targeted in the treat-
ment of hypertension through ACE inhibitors, however current inhibitors are known to cause severe
side effects. Therefore, there is a requirement for a new generation of ACE inhibitors and structural
information will be invaluable in their development. ACE is a challenging enzyme to work with due
to its extensive glycosylation. As such, the Drosophila melanogaster ACE homologue, AnCE, which
shares 60% sequence similarity with human ACE, can be used as a model for studying inhibitor
binding. The presence of ligands originating from the crystallisation condition at the AnCE active
site has proved an obstacle to studying the binding of new inhibitor precursors. Here we present
the crystal structure of AnCE (in a new crystal form) at 1.85 Å resolution, using crystals grown under
different conditions. This new structure may be more suitable for studying the binding of new com-
pounds, with the potential of developing a new generation of improved ACE inhibitors.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Angiotensin-I converting enzyme, ACE (EC 3.4.15.1) is a zinc
dependent dipeptidyl carboxypeptidase with an essential role in
mammalian blood pressure regulation. ACE is an integral compo-
nent of the renin–angiotensin aldosterone system (RAAS), a com-
plex hormone system that is the main mechanism for blood
pressure homeostasis in mammals. The primary function of ACE
in the RAAS is to produce the potent vasoconstrictor angiotensin
II from its inactive precursor angiotensin I, thereby increasing
blood pressure. ACE also acts to increase blood pressure by
destroying the peptide bradykinin, a potent vasodilator [1–4]. As
such, ACE has long been targeted in the treatment of hypertension
and other cardiovascular ailments [5–11]. Whilst ACE inhibitors
have proven to be highly effective, there are a number of side
effects associated with their use. These range from relatively mild:
a persistent dry cough, to potentially fatal: angioedema [12].
Two isoforms of ACE are found in humans: somatic (sACE) and
testis (tACE) ACE [13]. Both are transcribed from the same twenty-
six exon gene. sACE consists of two homologous domains arranged
in tandem, the N- and C-terminal domains, each with its own func-
tional active site. In contrast, tACE transcription is initiated from anintragenic promoter, resulting in a single domain enzyme identical
to the C-domain of sACE [14–17].
Although the two domains of sACE share approximately 60%
amino acid sequence identity, they have distinct biophysical and
biochemical properties [18,19]. Crucially, the C-domain hydrolyses
angiotensin I to angiotensin II much more efficiently than the
N-domain and appears to be sufficient for in vivo blood pressure
regulation [20].
The two domains of sACE are likely to be the result of a gene
duplication event, which would have enabled the N-domain to
evolve and acquire new functions [16]. There is evidence for the
N-domain being involved in a number of other physiological pro-
cesses, including inflammation and immunity [21,22]. As current
inhibitors are unable to discriminate between the N- and
C-domains, it is these newly acquired functions of the N-domain
that are thought to be the major cause of the side effects associated
with the use of ACE inhibitors.
It is therefore clear that there is a requirement for a new gener-
ation of domain specific ACE inhibitors and structural information
will no doubt be invaluable in achieving this. The first ACE struc-
ture, of human tACE, was reported in 2003 [23] however due to
its extensive glycosylation, estimated at 50% by weight [1], human
ACE is a challenging enzyme to work with.
An ACE homologue from Drosophila melanogaster, AnCE, shares
approximately 60% overall sequence similarity with each domain
of human ACE (considerably higher in key catalytic regions).
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studying inhibitor binding to ACE [24–26].
The crystal structure of AnCE was first determined in 2003 at
2.40 Å resolution using crystals in the P21 space group (form I
structure) [27]. This was followed in 2010 by a series of higher res-
olution structures of AnCE in complex with various inhibitors that
were obtained from crystals in the R3 space group (form II struc-
ture) [24]. Over the five years that have followed, a number of fur-
ther AnCE-inhibitor complex structures have been reported using
the form II structure [24–26,28].
All of the current ACE inhibitors are competitive inhibitors,
which use either a carboxyl or sulphydryl group toFig. 1. Comparison of the overall appearance of the form II AnCE structure with the new s
2X8Y) with the catalytic zinc ion visible as a grey sphere alongside a citrate ion from the
Helices a1–a3 form a lid capping the substrate binding channel. N-linked glycosylation vi
of the new AnCE structure is identical to the form II structure, apart from the absence
structure are shown as cyan sticks co-ordinating the catalytic zinc ion (grey sphere) and
involved in co-ordination are shown as orange spheres, one of which completes the co-ord
between the citrate ion and active site residues are shown as black dashes. (d) The sam
positions of these residues are unchanged between the two structures. The active site
solution, which makes additional interactions with His397 and His337 not replicated by t
grey and orange spheres, respectively. Although the zinc co-ordinating water molecule
Electron density at the active site of the new structure showing key side chains as pinkco-ordinate the catalytic zinc ion. The structure based design
of a new generation of ACE inhibitors will need to begin by
studying the mechanism of binding of novel compounds which
are much less potent inhibitors than those currently available.
By using structural information to study their mode of
inhibition it would then be possible to exploit features of their
interactions with the ACE active site to develop them into
better inhibitors.
The crystallisation condition that gives rise to the R3 crystals
used to determine the form II AnCE structure contains a high con-
centration of citrate ion [24]. In the absence of an inhibitor a citrate
ion co-ordinates the active site catalytic zinc ion. New, weakertructure presented here. (a) The overall structure of the form II AnCE structure (PDB
crystallisation media (green sticks) at the centre of the substrate binding channel.
sible at Asn53, Asn196 and Asn311 is shown as green sticks. (b) The overall structure
of N-linked glycosylation at Asn196. (c) Key active site residues from the form II
a citrate ion from the crystallisation condition, green sticks. Two water molecules
ination of the zinc ion by mediating an interaction with the citrate. Hydrogen bonds
e selection of residues as in (c) shown as magenta sticks for the new structure. The
of the new structure contains a malate ion (green sticks) from the crystallisation
he citrate. The zinc ion and water molecules involved in co-ordination are shown as
from the form II structure is conserved it does not interact with the malate ion. (e)
sticks and the malate ion as cyan sticks.
Table 1
X-ray data collection, processing and refinement statistics.
Beamline I24 – Diamond Light Source, Didcot, UK
Detector PILATUS 6M
Wavelength (Å) 1.000
Resolution range (Å) 68.52–1.85
Space group P212121
Cell dimensions (Å, ) a = 86.12, b = 94.90, c = 99.03, a = 90.00,
b = 90.00, c = 90.00
Molecules per asymmetric unit 1
Solvent content (%) 56.87
Unique/Total reflections 219797/68121
Completeness (%) 97.8 (89.5)
Multiplicity 3.2 (2.2)
#Rmerge (%) 6.1 (58.8)
+Rpim (%) 5.0 (49.2)
Mean I/r(I) 10.6 (2.2)
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very difficult to study their binding.
Here we present a new structure of AnCE at 1.85 Å resolution
from crystals in the P212121 space group grown in the absence of
citrate ions. The atomic coordinates and structure factors have
been deposited in the Protein Data Bank with accession code
PDB: 5A2R. Comparison with the form I and form II structures
obtained previously shows that overall the three are very similar,
thus we can confidently use the new crystallisation condition for
future inhibitor binding studies. There are some small differences
resulting from crystal packing interactions, some of which are
explored in detail in this report. The main focus of the comparison
is the form II structure, as this has previously been used exten-
sively for ligand binding studies.§Rcryst/##Rfree (%) 16.31/18.56
Wilson B factor (Å2) 25.0
Average B factor (Å2)
Overall 25.59
Protein 24.35
Ligands:
Zinc 21.00
Tris 41.90
Malate 28.33
Glycosylated carbohydrates 49.35
Solvent 34.73
R.m.s.d from ideal values in
bond lengths (Å)
0.007
R.m.s.d from ideal values in
bond angles ()
1.28
Ramachandran plot statistics (%)
Favoured 99.16
Disallowed 0
PDB code 5A2R
# Rmerge ¼
P
hkl
P
ijIiðhklÞ  hIðhklÞij=
P
hkl
P
iIiðhklÞ, where Ii(hkl) is the intensity of
ith measurement and <I(hkl)> is the average of symmetry-related observations of a
unique reflection.
+ Rpim ¼
P
hkl
ﬃﬃﬃﬃﬃﬃﬃ
1
n1
q Pn
i¼1jIiðhklÞ  hIðhklÞij=
P
hkl
P
iIiðhklÞ.
§ Rcryst ¼
P
hjFo  Fc j=
P
hFo , where Fo and Fc are observed and calculated structure
factor amplitudes of reflection h, respectively.
## Rfree is equal to Rcryst for a randomly selected 5% subset of reflections.
##Ramachandran plots were prepared for all residues other than Gly and Pro.
Table 2
List of hydrogen bond interactions formed by the citrate and malate ions in the active
sites of the form II and form III AnCE structures, respectively.
Interacting atoms Distance (Å)
Citrate atom
OA1 Water 2.61
OA2 Y504OH 2.87
OA2 Q265NE2 3.28
OA2 K495NZ 3.22
OHB Water 2.86
OG2 Water 3.20
OB1 Water 2.96
Malate atom
O1 Y504OH 2.52
O1 Q265NE2 3.02
O1 K495NZ 2.70
O2 Water 2.79
O4 H497NE2 2.95
O4 H337NE2 2.672. Results and discussion
In contrast to the crystals used to determine the form I and form
II structures, which belonged to the P21 and R3 space groups,
respectively, the crystals obtained here were found to belong to
the P212121 space group. As for the form II structure there is one
molecule per asymmetric unit. Electron density was observed for
residues 18-614 (20-614 in the form II structure). The catalytic zinc
ion found in all ACE homologues was modelled in the active site
along with a malate ion from the crystallisation media (Fig. 1d).
The overall structure is predominantly helical, consisting of
twenty-one a-helices, nine 310 helices and two anti-parallel
b-strands. Key features of the enzyme that are characteristic of
ACE homologues include a large central channel with the active
site at its centre which is capped by a lid formed by helices a1,
a2 and a3 (Fig. 1b). The overall topology of this structure is
identical to that of the form I and form II structures reported
previously; Ca RMS deviation 0.27 and 0.33 Å, respectively. There
are no Ramachandran outliers.
As illustrated in Fig. 1e, a malate ion was modelled in the active
site electron density. The malate ion binds in a similar manner to
the citrate ion in the form II structure and it is therefore not
surprising that the positions of the active site residues are
unchanged in the two structures.
Both the malate ion in this structure and the citrate ion in the
form II structure interact with active site residues Tyr504,
Gln265 and Lys495 through a carboxylate group. The second car-
boxylate group of the malate ion also contacts His494 and
His337, interactions that are not replicated by the citrate (Fig. 1).
The remaining two carboxylate groups of the citrate ion make
water mediated interactions with active site residues Asp399,
Tyr507 and Glu395, the latter of which is also involved in zinc
co-ordination. Crucially, the citrate ion also forms a water-
mediated interaction with the catalytic zinc ion. Although the
water molecule involved in this is conserved in the form III struc-
ture, the orientation of the malate ion means that it is unable to
replicate this interaction. A summary of hydrogen bond interac-
tions made by the citrate and malate ions is presented in Table 2.
The lack of zinc co-ordination by the malate ion indicates that it
may not be held so tightly in the active site and so would be more
easily displaced by weaker inhibitors. This could make this crys-
tallisation condition more suitable for developing new inhibitors.
A noticeable difference between the three structures is in the
glycosylation profiles of the enzymes. No glycosylation was
reported for the form I structure, whereas electron density is
clearly visible at three N-linked glycosylation sites (Asn53,
Asn196 and Asn311) in the form II structure (Fig. 1a). The form II
structure and the new structure presented here were both deter-
mined using AnCE expressed by Pichia pastoris. In spite of this, elec-
tron density is only observed at two of these sites, Asn53 andAsn311, in the new structure (Fig. 1b). This is most likely due to
differences in crystal packing.
In the form II structure each molecule contacts four other mole-
cules, there are therefore two different interfaces between symme-
try related molecules, as illustrated in Fig. 2a. The first involves
helices a1 and a2 of the N-terminal lid of one molecule and regions
Fig. 2. Crystal contacts in the two AnCE structures. (a) In the form II structure there are two different interfaces between symmetry molecules. To illustrate this three AnCE
molecules are shown as cartoon and surface representations. The central molecule is shown as cyan and the two symmetry molecules in grey. The two interfaces are labelled
as interface 1 and interface 2. The N-linked glycosylation at Asn196 is shown as cyan sticks and is an integral part of interface 2. (b) The three different interfaces between
symmetry molecules in the new structure. The interfaces are labelled 1–3. The molecules are shown as surface and cartoons with the central molecule in magenta and the
three symmetry molecules in grey.
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interface is significantly larger than the first. It involves helices
a3, a6, a8 and the N-linked glycosylation at Asn196 of the first
molecule interacting with helices a5, a8 and a12 of the symmetry
molecule.
In the new structure each molecule contacts six symmetry
molecules, involving three different interfaces, as illustrated in
Fig. 2b. The first interface involves a5, a8 and a9 of the first
molecule interacting with regions of a1, a3, a8, a18 and a20 of
the symmetry molecule. The second interface is similar to the
first interface in the form II structure, involving a1, a2 and a4
of the N-terminal lid of the first molecule contacting a5 and a8
of the symmetry related molecule. The third interface is much
smaller than any of the other interfaces, involving Lys20 of a1
of the first molecule and four residues from a18 of the symmetry
molecule.
The absence of N-linked glycosylation at Asn196 in the new
structure can be explained by examining these interactions withsymmetry related molecules. As illustrated in Fig. 2a, this glycosy-
lation is an integral part of the second interface in the form II struc-
ture, forming hydrogen bond interactions with Arg157, Arg238,
Lys241 and His242 of the symmetry related molecule (Fig. 3).
These interactions hold the glycan chain in a single conformation,
making it visible in the structure. Conversely, in the new structure
there is no symmetry related molecule in this region. The glycan
chain is therefore likely to be highly mobile hence no electron den-
sity is visible.
There are further differences between the new structure and
the form II structure associated with this interface. As illustrated
in Fig. 4, the top of helix a2 and the loop region between a2 and
a3 is shifted by up to 1.3 Å towards the symmetry molecule in
the form II structure. This is driven by hydrogen bonding between
the main chains of Tyr88 and Gln89 with the side chain of Asn601
of the symmetry molecule, and with the side chains of Gln84 and
Arg86 with the side chains of Lys241 and Asp245, respectively of
the symmetry related molecule.
Fig. 3. Crystal contacts at interface 2 in the form II structure stabilize the N-linked
glycosylation at Asn196. The glycosylation is shown as blue sticks with hydrogen
bonding residues from the symmetry molecule in grey. Hydrogen bonds are shown
as black dashes.
C. Harrison, K.R. Acharya / FEBS Open Bio 5 (2015) 661–667 665More subtle differences between the two structures are concen-
trated around the first interface in the form II structure and the
second interface of the new structure. This is not surprising as
there is considerable overlap between these two interfaces. In
the form II structure, the side chain of Lys38 is positioned to hydro-
gen bond with Asp305 of the symmetry molecule. In the new
structure there are no symmetry residues within hydrogen bond-
ing distance of Lys38. A 5 Å movement of the side chain is observed
that enables it to form a hydrogen bond with neighbouring Glu35,Fig. 4. Interactions between the symmetry molecules at interface 2 in the form II structu
with one molecule shown in cyan and the symmetry molecule in grey and (b) close-up v
grey and those from the central molecule in cyan. Corresponding residues from the new
peptide backbone in this region. Hydrogen bonding interactions with Asn601, Asp245 an
loop between a2 and a3 towards the symmetry molecule, resulting in movement of theas illustrated in Fig. 5. In order to accommodate this interaction
there is a small change in the position of the Glu35 side chain in
the new structure, which results in one of the two interactions
with Arg39 being lost, Fig. 5b.
Moving further along the helix to the area where there is most
overlap between the two interfaces more small changes are
observed. In the form II structure Glu64 hydrogen bonds to
Lys291 of the symmetry related molecule and Lys60 within the
molecule. In the new structure Glu64 adopts a different conforma-
tion so as to avoid a clash with Asn610 of the symmetry molecule.
This results in the intra-molecular interaction with Lys60 being
lost (Fig. 5d). Similarly, Ile65 exists as different rotamers in the
two structures. As illustrated in Fig. 5d, this is to avoid a clash with
Val484 of the symmetry related molecule in the new structure.
3. Conclusions
We present here a new structure of the D. melanogaster ACE
homologue, AnCE in a new space group to the two previous struc-
tures. Although there are some minor differences between the
structures caused by interactions with symmetry related mole-
cules, the overall folds are identical, indicating that this is a valid
structure. The absence of a citrate ion co-ordinating the catalytic
zinc ion may make this crystallisation condition more suitable
for studying the binding of new, weaker inhibitors, an important
starting point in the development of a new generation of ACE
inhibitors.
4. Materials and methods
4.1. Protein expression and purification
AnCE was expressed using P. pastoris and purified by hydropho-
bic interaction chromatography and size exclusion chromatogra-
phy as described previously [24,29]. Briefly, the culture
supernatant was treated with 1.5 M ammonium sulphate, 20 mM
Tris, pH 8 and clarified by centrifugation at 4000g, 4 C. The clari-
fied supernatant was loaded onto a phenyl sepharose fast flow 6
column (GE Healthcare) previously equilibrated with 1.5 Mre results in movement of a2 by 1.3 Å. (a) A surface representation of the interface
iew of the interface. Interacting residues from the symmetry molecule are shown in
structure are superposed and shown in magenta to illustrate the movement of the
d Lys241 of the symmetry molecule in the form II structure pull part of a2 and the
peptide backbone by up to 1.3 Å compared to in the new structure.
Fig. 5. Comparison of positions adopted by side-chains at interface 2 in the form II structure and interface I in the new structure. (a) Surface representation of interface 2 of
the form II structure with AnCE shown in cyan and the symmetry molecule in grey. Key interacting residues at this interface are shown as sticks with a close-up view in (c).
For comparison, equivalent residues from the new structure are shown in (c) as magenta sticks. The Lys38 side chain moves by approximately 5 Å in the two structures to
hydrogen bond with Asp305 of the symmetry molecule in the form II structure and Glu35 of the same molecule in the new structure. (b) Surface representation of interface 1
in the new structure, which overlaps significantly with interface 2 in the form II structure. The AnCE surface is shown in cyan with the symmetry molecule in coral. Key
interacting residues are shown as sticks with a close-up view in (d), where symmetry molecule residues are in coral and AnCE residues from the new structure in magenta
with residues from the original structure shown in cyan for comparison. To avoid a clash with Asn610 of the symmetry molecule, Glu64 in the new structure adopts a
different conformation to in the form II structure where it forms a hydrogen bond with Lys291 of the symmetry molecule. Similarly, to avoid a clash with Val484 of the
symmetry molecule Ile65 exists as a different rotamer in the two structures.
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with a gradient of decreasing salt and fractions containing AnCE
were pooled and concentrated to a final volume of approximately
1.5 ml. Concentrated fractions were dialysed into 150 mM NaCl,
20 mM Tris pH 8 and loaded onto a superdex 200 16/600 column
(GE healthcare) equilibrated with this buffer. Fractions containing
AnCE were pooled together and dialysed into 5 mM HEPES pH 7.5,
0.1 mM PMSF before being concentrated to 15 mg ml1 for
crystallisation.
4.2. X-ray crystallography
A range of crystallisation conditions were screened using 96-
well pre-prepared screens (Molecular Dimensions) and the
Phoenix protein crystallisation robot (Art Robbins Instruments)
using the sitting drop vapour diffusion method. 300 nl drops were
set-up with a 1:1 ratio of protein:reservoir and plates were incu-
bated at 21 C. Crystals were grown in a condition containing
0.1 M MMT buffer pH 4.0 and 25% w/v PEG 1500. Crystals weretaken directly from this drop for data collection at Diamond Light
Source (Oxon, UK) on beamline I24.
Data were collected to 1.85 Å resolution. Raw data images were
processed using MOSFLM [30,31] and Aimless [32] from the CCP4
suite [33]. This indicated that the crystals belonged to the space
group P212121 with one molecule per asymmetric unit. Initial
phases were calculated by molecular replacement using Phaser
[34] with the previously determined structure of AnCE (PDB code
2X8Y) as the search model. The resulting model was refined using
REFMAC5 [35,36] and 5% of reflections were separated as the Rfree
set for use in cross-validation. After an initial round of rigid body
refinement rounds of restrained refinement with manual adjust-
ments of the model using COOT [37] were performed. Water mole-
cules were added where Fo–Fc electron density peaks exceed 3r
and potential hydrogen bonds could be made. Ligands were added
to the active site based on interpretation of the electron density
and further rounds of refinement were performed. Validation
was performed with the aid of the program MOLPROBITY [38].
There were no residues in the disallowed regions of the
C. Harrison, K.R. Acharya / FEBS Open Bio 5 (2015) 661–667 667Ramachandran plot. Crystallographic data statistics are sum-
marised in Table 1. All figures were drawn using PyMOL [39].
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